CA-PSMF
The Patient Safety Movement Foundation (PSMF) is bringing together some of the world’s foremost experts and advocates on patient safety at their 11th annual World Patient Safety, Science & Technology Summit on September 6-7, 2024. Hosted on the campus of the University of California, Irvine, a hub for innovative research, the two-day conference will address some of the most critical issues and pioneering solutions around protecting patients from preventable harm in healthcare settings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715610848/en/
Patient Safety Movement Foundation's 11th Annual World Patient Safety, Science & Technology Summit, September 6-7, at the University of California, Irvine (Photo: Business Wire)
Distinguished speakers from around the world will discuss and present on groundbreaking solutions in patient safety, including leveraging real-time data from electronic medical records, the transformative impact of artificial intelligence in healthcare, implementing best practices for patient safety, championing data transparency, and cultivating a culture of safety systemwide.
The featured keynote presenters are PSMF Founder Joe Kiani; WHO Director-General Dr. Tedros Ghebreyesus; president emeritus and senior fellow at the Institute for Healthcare Improvement, Dr. Donald M. Berwick; Surgeon General of California, Dr. Diana Ramos; Director of the Center for Quality Improvement and Patient Safety, Dr. Craig Umscheid; and Chief Medical Officer at WebMD, Dr. John Whyte. Panelists represent a broad spectrum of healthcare administrators, clinicians, patient safety experts and advocates, academic researchers, MedTech executives, patients, and their families.
“We can’t stop until there is ZERO patient and clinician harm in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement Foundation. “We have the know-how and the innovations to create a safer healthcare system today, but we must take action. I think AI, if used properly, will be a game changer. I hope to see every healthcare system represented at our global Summit.”
“Patient safety is advancing faster than ever before thanks to new innovations and the dedication and commitment of our global patient safety community and the patients themselves,” said PSMF CEO Dr. Michael Ramsay. “We look forward to sharing what we know and learning about everyone’s challenges. This Summit will be a unique opportunity to make lifelong connections that will support worldwide efforts toward achieving ZERO patient harm.”
For more information, including the latest agenda, and to register, visit https://psmf.org/summits/11th-annual-world-patient-safety-science-technology-summit/.
THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715610848/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom